PHGE - BiomX Inc.
NYSE
->
Healthcare
->
Biotechnology
Ness Ziona,
Israel
Type: Equity
PHGE price evolution
PHGE
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $23.54 | $31.61 | $43.01 | $14.91 |
| Short term investments | ||||
| Net receivables | $0.95 | $0.62 | $2.24 | $0.57 |
| Inventory | ||||
| Total current assets | $28.32 | $35.08 | $47.1 | $17.63 |
| Long term investments | ||||
| Property, plant & equipment | $16.28 | $17.37 | $18.72 | $7.4 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $59.98 | $68.62 | $81.61 | $25.03 |
| Current liabilities | ||||
| Accounts payable | $2.78 | $3.24 | $3.69 | $1.38 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $8.94 | $7.3 | $10.71 | $11.18 |
| Long term debt | $5.4 | |||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $22.08 | $41.19 | $58.73 | $21.95 |
| Shareholders' equity | ||||
| Retained earnings | -$166.18 | -$175.83 | -$180.3 | -$162.97 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $14.91 | $31.33 | $62.1 | $37.24 |
| Short term investments | ||||
| Net receivables | $0.57 | |||
| Inventory | ||||
| Total current assets | $17.63 | $36.88 | $66.64 | $60.67 |
| Long term investments | ||||
| Property, plant & equipment | $7.4 | $8.65 | $9.83 | $2.23 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $9.7 | |||
| Total investments | ||||
| Total assets | $25.03 | $45.53 | $77.99 | $70.36 |
| Current liabilities | ||||
| Accounts payable | $1.38 | $0.82 | $2.79 | $6.3 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $11.18 | $7.94 | $11.04 | $7.16 |
| Long term debt | $5.4 | $10.59 | $14.41 | |
| Total noncurrent liabilities | $5.73 | |||
| Total debt | ||||
| Total liabilities | $21.95 | $24.49 | $30.45 | $12.89 |
| Shareholders' equity | ||||
| Retained earnings | -$162.97 | -$136.8 | -$108.48 | -$72.26 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $10.53 | $9.72 | $6.79 | $5.27 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.01 | $0.01 | $0 | |
| Interest expense | $20.89 | $12.18 | -$10.63 | -$0.3 |
| Net income | ||||
| Net income | $9.64 | $4.47 | -$17.33 | -$5.49 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $25.35 | $27.22 | $30.26 | |
| Operating income | -$30.26 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.02 | $0.07 | ||
| Interest expense | -$1.1 | -$1.15 | ||
| Net income | ||||
| Net income | -$26.17 | -$28.32 | -$30.09 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $0.72 | $0.72 | $0.66 | $1.95 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $38.77 | $38.77 | $38.98 | $2.9 |
| Effect of exchange rate | -$0.01 | -$0.05 | -$0.03 | $0.01 |
| Change in cash and equivalents | $8.79 | $16.85 | $28.25 | -$16.43 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | -$30.09 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$24.45 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $1.95 | -$2.11 | $16.17 | -$10.86 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $2.9 | $0.29 | $37.28 | $0.13 |
| Effect of exchange rate | $0.01 | $0.11 | -$0.03 | |
| Change in cash and equivalents | -$16.43 | -$30.8 | $25.85 | -$35.17 |
News
Fundamentals
| Market cap | $7.45M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 18.18M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$8.71M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.86 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 1.29 |
| EPS | -$0.48 |
|---|---|
| ROA | -14.80% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.17 |
| Quick ratio | N/A |